

A Variant in *FTO* shows association with melanoma risk not due to BMI

Mark M Iles et al*

*a full list of authors appears in the main paper

Contents

1. Supplementary Tables
2. Supplementary Figures
3. Supplementary Note
 - Supplementary analyses and results
 - Functional evidence
 - Replication samples
 - References
4. GenoMEL membership
5. Q-MEGA and AMFS investigators

Supplementary Tables

Supplementary Table I Numbers of cases and controls from each study and numbers of cases and controls with BMI data from each study.

	cases	controls	cases with BMI	controls with BMI
GenoMEL Phase 1	1,353	3,566	144	1,355
GenoMEL Phase 2	1,449	4,043	466	1,541
Leeds case-control*	680	1,785	664	302
Harvard*	≥421	≥2,349	421	2,349
Australia	2,168	4,385	413	1210
Italy	537	430	143	122
Houston	1,802	1,025	929	891
Iceland	926	34,656	679	25,189
the Netherlands	729	1,651	711	1,613
Vienna	1,174	929	542	406
Milan	555	368	0	0
Sweden	1,010	499	0	0
Valencia	576	1,769	0	0
Zaragoza	287	1,778	0	0
Total	13,667	59,233	5,112	34,978

* 421 cases and 2,349 controls were genotyped for rs16953002 and 494 cases and 5,627 controls imputed for rs8050136. Leeds case-control sample genotyped for rs16953002 but not rs8050136. Case/control numbers for rs8050136 are 13,060/60,726.